Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia

被引：0
|
作者：
Bari, Mohammed [3 ]
Shiwach, Raj [1 ]
Jimenez, Roland [2 ]
Siegert, Scott [2 ]
O'Brien, Christopher [2 ]
机构：
[1] InSite Clin Res, Desoto, TX USA
[2] Neurocrine Biosci Inc, San Diego, CA USA
[3] Synergy Clin Res Ctr, San Diego, CA USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S27.001
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2
    Factor, Stewart
    Hauser, Robert
    Mandri, Daniel
    Castro-Gayol, Julio
    Jimenez, Roland
    Siegert, Scott
    O'Brien, Christopher
    [J]. NEUROLOGY, 2016, 86
  • [2] Efficacy of Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia: Results of a Long-Term Extension Study (KINECT 3 Extension)
    Grigoriadis, Dimitri
    Comella, Cynthia
    Remington, Gary
    Jimenez, Roland
    Burke, Joshua
    Christopher, O'Brien
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S213 - S214
  • [3] Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension)
    Factor, Stewart
    Comella, Cynthia
    Correll, Christoph
    Liang, Grace
    Burke, Joshua
    O'Brien, Christopher
    [J]. NEUROLOGY, 2017, 88
  • [4] RESPONSE TO TREATMENT WITH VALBENAZINE (NBI-98854) IN SUBJECTS WITH TARDIVE DYSKINESIA
    Kane, John
    Josiassen, Richard
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    Liang, Grace
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S119 - S119
  • [5] VALBENAZINE (NBI-98854) FOR THE TREATMENT OF TARDIVE DYSKINESIA: ANALYSIS BY UNDERLYING PSYCHIATRIC DIAGNOSIS IN PHASE III KINECT 3 STUDY
    Josiassen, Richard
    Kane, John
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    Liang, Grace
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S217 - S217
  • [6] EFFICACY AND SAFETY OF VALBENAZINE (NBI-98854) IN SUBJECTS WITH TARDIVE DYSKINESIA: RESULTS OF A LONG-TERM STUDY (KINECT 3 EXTENSION)
    Siegert, S.
    Factor, S.
    Liang, G.
    Burke, J.
    [J]. PARKINSONISM & RELATED DISORDERS, 2018, 46 : E35 - E35
  • [7] Kinect 2: NBI-98854 treatment of moderate to severe tardive dyskinesia
    O'Brien, C. F.
    Jimenez, R.
    Hauser, R. A.
    Factor, S. A.
    Mandri, D. F.
    Castro-Gyol, J. C.
    [J]. MOVEMENT DISORDERS, 2014, 29 : S305 - S306
  • [8] KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia
    Hauser, Robert
    Factor, Stewart
    Marder, Stephen
    Knesevich, Mary Ann
    Ramirez, Paul Michael
    Jimenez, Roland
    Burke, Joshua
    Liang, Grace
    O'Brien, Christopher
    [J]. NEUROLOGY, 2016, 86
  • [9] KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia
    Factor, S. A.
    Hauser, R. A.
    Siegert, S.
    Liang, G. S.
    O'Brien, C. F.
    [J]. MOVEMENT DISORDERS, 2016, 31 : S692 - S692
  • [10] Twelve-week treatment of tardive dyskinesia with NBI-98854
    Jimenez, R.
    Shiwach, R.
    Bari, M.
    O'Brien, C. F.
    [J]. MOVEMENT DISORDERS, 2014, 29 : S304 - S305
12345